ERBB2 and central nervous system cancer: A total of 48 patients with BM were enrolled in the present study, with an mPFS of 7.97 months and an ORR of 58.4%; these results were comparable to the efficacy of other small‐molecule anti‐HER2 drugs against CNS cancer in HER2‐positive patients reported in the previous real‐world studies.15, 16, 17, 18